Simple blood tests may offer a new avenue for breast cancer risk assessment, potentially making screening more accessible and cost-effective. This capability could be particularly valuable in resource-limited settings or as an adjunct to existing mammography protocols. Analysis of nearly 20,000 women from the National Health and Nutrition Examination Survey revealed that elevated platelet-to-lymphocyte ratios (PLR) correlate with increased breast cancer prevalence, showing a 35% higher odds ratio among women with elevated inflammatory markers. Five additional inflammation indices—including neutrophil-to-lymphocyte ratio and systemic immune-inflammation index—demonstrated similar positive associations with cancer presence. The PLR metric achieved the strongest diagnostic performance with an area under the curve of 0.59, indicating modest but measurable predictive capability. This finding aligns with emerging research linking chronic inflammation to cancer development through mechanisms involving immune system dysfunction and cellular damage pathways. However, the diagnostic accuracy remains relatively modest, suggesting these markers would likely serve as supplementary screening tools rather than standalone diagnostic methods. The consistency of associations across diverse population subgroups strengthens the validity of these inflammatory biomarkers. While promising for population-level screening strategies, particularly in underserved communities, these blood-based indicators require validation in larger prospective studies before clinical implementation. The research represents an incremental advance in cancer biomarker development, offering potential cost savings and improved accessibility compared to current imaging-based screening approaches.